Skip to content
Company Analysis

TriSalus Life Sciences, Inc. TLSIW

A comprehensive view of key metrics, scores, and financial health for TriSalus Life Sciences, Inc.

Overview of TriSalus Life Sciences, Inc.

TLSIW NGM
Healthcare Medical Devices
TriSalus Life Sciences, Inc. (TLSIW), in the Medical Devices industry, last closed at $0.86, about 0.0% overvalued vs fair value, -16.5% 1Y return, ranked 982/1121 in sector.
$0.86
-9.47%
As of April 27, 2026
Previous close • Vol 90d: 170.0%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Completeness: 56%
Confidence: 36%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://trisaluslifesci.com
HQ Westminster, CO
Employees 110
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$29.4M
59%%
Gross Profit
$25.3M
59.2%%
Operating Income
$-36.2M
33.6%%
Net Income
$-30.0M
49.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
137.1%
Excellent

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating TriSalus Life Sciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
54
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
49
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 81% Coverage
Trade-Off Triangle Visualization A ternary plot showing TLSIW's balance between Growth (53.6%), Profitability (28.3%), and Safety (18.1%). Growth 54% Safety 18% Profitability 28%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

89th percentile vs peers
89
Key Signals
Rev Growth YoY 59.0% 91p Revenue CAGR 3Y 51.9% 87p
Strengths
  • Growth performance in top 20% of peers (percentile: 89)
  • Rev Growth YoY in top 20% of peers (59.0%, 91th percentile)
  • Revenue CAGR 3Y in top 20% of peers (51.9%, 87th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • ROIC in top 20% of peers (9.49, 97th percentile)
Risks

No significant risks identified for this axis.

Profitability

47th percentile vs peers
47
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

30th percentile vs peers
30
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for TriSalus Life Sciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info